Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss
Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended August 31, 2021. The firm
Read more
Mind Cure Health
Mind Cure Health Receives Ethics Approval For Psychedelic Integration Protocol Study
Mind Cure Health (CSE: MCUR) has seen its integration protocol research study receive unconditional ethics approval. The study is being
Read more
Mind Cure Health Begins Manufacturing Synthetic Ibogaine
Mind Cure Health (CSE: MCUR) this morning announced that it has begun the first stage of the manufacture of pharmaceutical
Read more
Mind Cure Health Appoints Rob Hill To Board Of Directors
Mind Cure Health (CSE: MCUR) this morning announced the appointment of Rob Hill to the firms board of directors. The
Read more
Mind Cure Launches Product Sales Division
Mind Cure Health (CSE: MCUR) continued its constant roll of news this week, announcing this morning that it has launched
Read more
Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury
Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one of its advisory board members
Read more
Mindcure Completes Beta Testing, Launches PsyCollage
Mind Cure Health (CSE: MCUR) has completed the beta testing phase for its proprietary bioinformatics platform. Referred to as PsyCollage,
Read more
Mind Cure Sees Warrants Approved For Trading
Mind Cure Health (CSE: MCUR) is looking to provide a boost to its liquidity for shareholders. The company this morning
Read more
Mind Cure Set To Launch Products Into Psychedelic Therapy Adaptogen Supplement Category
Mind Cure Health (CSE: MCUR) has completed the development of its first products. The company has completed the proprietary formulations
Read more
Mind Cure Doubles Bought Deal Financing To $20 Million
Strong demand continues within the psychedelics space, with Mind Cure Health (CSE: MCUR) announcing earlier today that it has doubled
Read more